

XVI Congres de la Societat Catalano- Balear de Medicina Interna. Barcelona, 2-3 Juny, 2016

## Efectes de la Dieta Mediterrània en la

## Prevenció de la

## Malaltia Cardiovascular i el Càncer

## El Estudi PREDIMED

Dr. María-Isabel Covas NUPROAS Handelsbolag (NUPROAS HB) Cardiovascular Risk and Nutrition Research Group IMIM – Hospital del Mar Research Institut – Barcelona – Spain CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN)





10 M


1

#### **BEST WEAPONS AGAINST CHRONIC DEGENERATIVE DISEASES: DIET AND EXERCISE**





Mediterranean Diet Pyramid A contemporary approach to delicious, healthy eating



Illusionist by Caroge Middleton




#### Origin of the Mediterranean Diet

# Mar Mediterráneo Zona de Olivos Cuenca del Mediterráneo



## **Traditional Mediterranean Diet**

#### **HIGH CONSUMPTION**



2010 edition

s = Serving










## **Traditional Mediterranean Diet**

#### **MEDIUM/LOW CONSUMPTION**




### Mediterranean Food Pattern



- Increased Longevity
- Prevention of
  - CV mortality
  - Cancer mortality
  - CVD incidence
  - Metabolic syndrome
  - Diabetes
  - Dementia
  - Depression
- Scarcity of large randomized trials





Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990; 43:891-905; U.S. Preventive Task Force. Williams and Wilkins 1989; The Swedish Council of Technology Assessment in Health and Care., 1993; Agència d'Avaluació de Tecnologia Mèdica de Catalunya. Med Clin (Barc) 1995:105:740-743.




XVI Congres de la Societat Catalano-Balear de Medicina Interna. 2-3 Juny, 2016

## Mediterranean Diet and

## Cardiovascular Disease




#### Forest plot of the association between a 2-point increase of adherence score to the Mediterranean diet and the risk of mortality from or incidence of cardiovascular diseases.



Sofi F et al. Am J Clin Nutr 2010;92:1189-1196

010 by American Society for Nutrition


erican Journal of Clinical Nutritio



<sup>(</sup>Circulation, 1999; 99: 779-785)

#### The Effect of the Mediterranean Diet on the Primary Prevention of Cardiovascular Disease.The PREDIMED Study








To test the effect of wine intake on the risk of cardiovascular diseases



### PREDIMED TRIAL: DESIGN



#### **PREDIMED Steering Committee**

R. Estruch (chair); D. Corella; M.I. Covas; M.A. Martínez-Gonzalez; E. Ros; J. Salas-Salvadó


#### **PREDIMED Independent Data and Safety Monitoring Board**

Xavier Pi-Sunyer (chair). Columbia University. USA

Carlos A. González. Institut Catalá d'Oncologia (ICO), Spain

Frank B. Hu. Harvard University, USA

Joan Sabaté. Loma Linda University, CA, USA





### The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

APRIL 4, 2013

VOL. 368 NO. 14

#### Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Ramón Estruch, M.D., Ph.D., Emilio Ros, M.D., Ph.D., Jordi Salas-Salvadó, M.D., Ph.D., Maria-Isabel Covas, D.Pharm., Ph.D., Dolores Corella, D.Pharm., Ph.D., Fernando Arós, M.D., Ph.D., Enrique Gómez-Gracia, M.D., Ph.D., Valentina Ruiz-Gutiérrez, Ph.D., Miquel Fiol, M.D., Ph.D., José Lapetra, M.D., Ph.D., Rosa Maria Lamuela-Raventos, D.Pharm., Ph.D., Lluís Serra-Majem, M.D., Ph.D., Xavier Pintó, M.D., Ph.D., Josep Basora, M.D., Ph.D., Miguel Angel Muñoz, M.D., Ph.D., José V. Sorlí, M.D., Ph.D., José Alfredo Martínez, D.Pharm, M.D., Ph.D., and Miguel Angel Martínez-González, M.D., Ph.D., for the PREDIMED Study Investigators\*

ABSTRACT

Median Follow-up: 4.8 (2.8 to 5.8)

Participants: 7447



#### Intention-to-treat-analyses




















Table 1. Summary of Dietary Recommendations to Participants in the Mediterranean-Diet Groups and the Control-Diet Group.

Food	Goal
Mediterranean diet	
Recommended	
Olive oil*	≥4 tbsp/day
Tree nuts and peanuts <sup>*</sup>	≥3 servings/wk
Fresh fruits	≥3 servings/day
Vegetables	≥2 servings/day
Fish (especially fatty fish), seafood	≥3 servings/wk
Legumes	≥3 servings/wk
Sofrito:	≥2 servings/wk
White meat	Instead of red meat
Wine with meals (optionally, only for habitual drinkers)	≥7 glasses/wk
Discouraged	
Soda drinks	<1 drink/day
Commercial bakery goods, sweets, and pastries§	<3 servings/wk
Spread fats	<1 serving/day
Red and processed meats	<1 serving/day















Table 1. Summary of Dietary Recommendations to Participants in the Mediterranean-Diet Groups and the Control-Diet Group.

Low-fat diet (control)	
Recommended	
Low-fat dairy products	≥3 servings/day
Bread, potatoes, pasta, rice	≥3 servings/day
Fresh fruits	≥3 servings/day
Vegetables	≥2 servings/wk
Lean fish and seafood	≥3 servings/wk
Discouraged	
Vegetable oils (including olive oil)	≤2 tbsp/day
Commercial bakery goods, sweets, and pastries§	≤1 serving/wk
Nuts and fried snacks	≤1 serving /wk
Red and processed fatty meats	≤1 serving/wk
Visible fat in meats and soups¶	Always remove
Fatty fish, seafood canned in oil	≤1 serving/wk
Spread fats	≤1 serving/wk
Sofrito‡	≤2 servings/wk



### PREDIMED INTERVENTION

#### Strategies for behavior change


- Repeated personal contacts: every 3-mo.
- Group sessions: every 3-mo.
- Holistic approach
  - Written information
  - Self-monitoring
  - Individualized goal-setting
  - Quick feedback
  - Individual motivational interviews (every 3-mo.)
    - adapted to the patient's features
      - clinical condition
      - preferences
      - beliefs
    - expressed in servings/d to improve understanding



## PREDIMED INTERVENTION Strategies for behavior change

- Additional strategies
  - -Seasonal buying lists
  - -Menus and recipes
- Only in the 2 MeDiet groups
- Provision of key food items for free













#### Control Group: Small gifts non-related with food


## Results-Adherence to Mediterranean Diet (14-points score, Schröder H et al. J Nutr 2011)



#### Adherence to MedDiet plus Virgin Olive Oil intervention











#### Kaplan-Meier Estimates of the Incidence of the Primary End-point





Table 3. Outcomes According to Stu	ıdy Group.*				
End Point	Mediterranean Diet with EVOO (N=2543)	Mediterranean Diet with Nuts (N=2454)	Control Diet (N=2450)	P Va	lue†
	- I+ - 1			Mediterranean Diet with EVOO vs. Control Diet	
Stratified by recruiti BMI, Waist-to height, a	ing Center and adjus		•		noking,
∫ Stratified by recruiting smoking	g Center and adjuste	d by age, sex,	family histor	y of CHD, and	1
¶ Additionally adjusted diabetes at baseline	by BMI, Waist-to hei	ght, and hype	rtension, dys	lipidemia and	k






## **The PREDIMED Study-Conclusions**

- 1. Among individuals at cardiovascular risk, a traditional Mediterranean diet supplemented with Extra Virgin Olive Oil or with Nuts promoted a 30% reduction in the incidence of major cardiovascular events.
- 2. Results of the PREDIMED Study provide first level evidence on the benefits of the traditional Mediterranean diet on the primary prevention of cardiovascular disease.




The PREDIMED Study (n= 3541 non-diabetes at baseline).Cumulative diabetes incidence by group of intervention. Aalen-Nelson curves with outcome of diabetes onset and exposure to MedDiet intervention group vs. control



Salas-Salvadó et al. Ann Int Med, 2014


















XVI Congres de la Societat Catalano-Balear de Medicina Interna. 2-3 Juny, 2016

## Mediterranean Diet and

Cancer

#### Forest plot of the association between a 2-point increase of adherence score to the Mediterranean diet and the risk of mortality from or incidence of neoplastic diseases



Sofi F et al. Am J Clin Nutr 2010;92:1189-1196

10 by American Society for Nutrition

100



#### Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies. Overall cancer mortality

5.					Risk ratio	Risk ratio
	Study or subgroup	Log [Risk ratio]	SE	Weight	IV, Random, 95% CI	I IV, Random, 95% CI
11	1.12.1 cohort					
	Buckland et al. 2011	-0.0834 0.	).1042	5.5%	0.92 [0.75, 1.13]	-+
Rinky.	Cuenca-García et al. 2014	0.4886 0.	).2974	1.1%	1.63 [0.91, 2.92]	<u>+</u>
	George et al. 2014	-0.2231 0.	0.0681	8.0%	0.80 [0.70, 0.91]	-
X	Harmon et al. 2015 M	-0.2107 0.	0.0393	10.4%	0.81 [0.75, 0.87]	-
No.	Harmon et al. 2015 W	-0.1744 0.	0.0511	9.5%	0.84 [0.76, 0.93]	-
10	Knoops et al. 2004	-0.1054 0.	0.1282	4.3%	0.90 [0.70, 1.16]	-+
S. A.	LopezGarcia et al. 2014 M	-0.1278 0.	.1705	2.8%	0.88 [0.63, 1.23]	-+
A.	LopezGarcia et al. 2014 W	-0.2231 0.	.2606	1.4%	0.80 [0.48, 1.33]	
A.R	Martinez-Gonzalez 2012	0.0296 0.	).1757	2.7%	1.03 [0.73, 1.45]	+
23	Menotti et al. 2011	-0.1744 0.	0.0647	8.3%	0.84 [0.74, 0.95]	-
No.	Reedy et al. 2014 M	-0.2231 0.	0.0195	11.8%	0.80 [0.77, 0.83]	
STA BAR	Reedy et al. 2014 W	-0.2357 0.	0.0334	10.9%	0.79 [0.74, 0.84]	
	Tognon et al. 2012	-0.0513 0.	0.0219	11.7%	0.95 [0.91, 0.99]	
	Vormund et al. 2014	-0.0305 0.	0.0215	11.7%	0.97 [0.93, 1.01]	4
	Subtotal (95% CI)			100.0%	0.87 [0.81, 0.93]	•
	Heterogeneity: $\tau^2 = 0.01$ ; $\chi^2 =$		0.0000	1); /² = 84	%	
8	Test for overall effect: $Z = 4.3$	34 ( <i>P</i> < 0.0001)				
	Total (95% CI)			100.0%	0.87 [0.81, 0.93]	•
56	Heterogeneity: $\tau^2 = 0.01$ ; $\chi^2 =$	= 79.77, df = 13 ( <i>P</i> <	0.0000	1); /² = 84	%	
	Test for overall effect: Z = 4.3	34 ( <i>P</i> < 0.0001)			0	0.01 0.1 1 10 100
	Test for subgroup differences	: not applicable				Favours high MD adherence Favours low MD adherence
134						

Schwingshackl and Hoffman.Cancer Medicine 2015

#### **RISK RATIO/ODDS RATIO OF CANCER TYPE INCIDENCE ASSOCIATED WITH THE HIGHEST ADHERENCE** TO MEDITERRANEAN DIETARY PATTERN.

<b>K</b> •	Outcome		No of studies	Study type	Risk ratio/odds ratio 95% CI
•	Colorectal	7	Combined	0.83	0.76–0.89
		3	Cohort	0.84	0.75–0.94
		4	Case-control	0.79	0.67–0.93
•	Breast	12	Combined	0.93	0 <b>.87–0.99</b>
		4	Cohort	0.99	0.89–1.12

- **Prostate** No significant association was observed
- between adherence to a Mediterranean **Gastric cancer**
- Diet and risk of mortality among cancer Liver cancer

Esophageal

## survivors or cancer recurrence.

- Head and necl
- Endometrial **Respiratory**

Bladder

Pancreatic

U.U1 COHOIL 0.33-1.14 Case-control 0.32 0.19-0.55 0.40-1.31 Combined 0.72 Cohort 0.98 Case-control 0.61 Cohort 0.10 Cohort 0.84 0.48 Case-control

0.82 - 1.170.29 - 1.290.10-0.70 0.69 - 1.020.35–0.66 n

Schwingshackl and Hoffman.Cancer Medicine 2015

3

3

2











#### Forest plot showing pooled risk ratio (RRs) with 95% CI for risk of

#### colorectal cancer for 3 cohort studies, and 4 case-control studies.

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 cohort					
Bamia et al. 2013	-0.1165	0.0544	18.2%	0.89 [0.80, 0.99]	
Fung et al. 2010	-0.1278	0.0833	12.5%	0.88 [0.75, 1.04]	
Reedy et al. 2008 M	-0.3285	0.0681	15.3%	0.72 [0.63, 0.82]	
Reedy et al. 2008 W Subtotal (95% CI)	-0.1165	0.1082	9.1% 55.1%		•
Heterogeneity: Tau <sup>2</sup> =	0.01: Chi <sup>2</sup> = 6.85	df = 3		. , .	•
Test for overall effect:				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
1.3.2 case-control					
Dixon et al. 2007	-0.2357	0.0765	13.7%	0.79 [0.68, 0.92]	
Grosso et al. 2014	-0.7765	0.2533	2.3%	0.46 [0.28, 0.76]	
Kontou et al. 2012	-0.1278	0.0237	25.1%	0.88 [0.84, 0.92]	•
Whalen et al. 2014 Subtotal (95% CI)	-0.2614	0.1906	3.8% 44.9%		•
Heterogeneity: Tau <sup>2</sup> =	0.01: Chi <sup>2</sup> = 8.52	2. df = 3	(P = 0.04)		•
Test for overall effect:		-			
Total (95% CI)			100.0%	0.83 [0.76, 0.89]	•
Heterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup> = 15.9	)8, df = 7	7 (P = 0.0)	(3); $I^2 = 56\%$	
Test for overall effect:		-		- F F	0.1 0.2 0.5 1 2 5 10
Test for subgroup diffe			1 (P = 0.1)	55), $I^2 = 0\%$	Favours high MD adherence Favours low MD adherence

Schwingshackl and Hoffman.Cancer Medicine 2015
















# Forest plot showing pooled risk ratio (RRs) with 95% CI for risk of breast cancer for 4 cohort studies and 8 case-control studies.

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 cohort					
Buckland et al. 2013	-0.0619	0.066	17.3%	0.94 [0.83, 1.07]	
Cade et al. 2011	-0.0408	0.1612	3.8%	0.96 [0.70, 1.32]	
Couto et al. 2013	0.3507	0.184	3.0%	1.42 [0.99, 2.04]	
Fung et al. 2006	-0.0202	0.0654	17.5%	0.98 [0.86, 1.11]	
Subtotal (95% CI)			41.7%	0.99 [0.89, 1.12]	◆
Heterogeneity: Tau <sup>2</sup> = 0.	00; Chi <sup>2</sup> = 4.48,	df = 3 (P	= 0.21);	$I^2 = 33\%$	
Test for overall effect: Z	= 0.09 (P = 0.93)				
1.2.2 case-control					
Bessaoud et al. 2012	-0.0305	0.2202	2.1%	0.97 [0.63, 1.49]	
Castello et al. 2014	-0.3011	0.2426	1.8%	0.74 [0.46, 1.19]	
Demetriou et al. 2012	-0.0101	0.1769	3.2%	0.99 [0.70, 1.40]	
Mourouti et al. 2014	-0.0943	0.0288	40.6%	0.91 [0.86, 0.96]	<b>*</b>
Murtaugh et al. 2008	-0.2744	0.1379	5.1%	0.76 [0.58, 1.00]	
Nkondjock et al. 2007	-0.6162	0.5897	0.3%	0.54 [0.17, 1.72]	· · · · · · · · · · · · · · · · · · ·
Pot et al. 2014	0.0392	0.202	2.5%	1.04 [0.70, 1.55]	
Wu et al. 2009	-0.3567	0.1925	2.7%	0.70 [0.48, 1.02]	
Subtotal (95% CI)			58.3%	0.90 [0.85, 0.95]	◆
Heterogeneity: Tau <sup>2</sup> = 0.	00; Chi <sup>2</sup> = 5.67,	df = 7 (P	= 0.58);	$I^2 = 0\%$	
Test for overall effect: Z					
Total (95% CI)			100.0%	0.93 [0.87, 0.99]	•
Heterogeneity: Tau <sup>2</sup> = 0.	00; Chi <sup>2</sup> = 12.96	df = 11	(P = 0.3)	0); $I^2 = 15\%$	0.2 0.5 1 2 5
Test for overall effect: Z					0.2 0.5 1 2 5 Favours high MD adherence Favours low MD adherence
Test for subgroup differe	$pcac: Chi^2 = 2.34$	df = 1	(P = 0.13)	12 - 57 39/	ravours nigh MD autherence Favours low MD autherence

Schwingshackl and Hoffman. Cancer Medicine 2015

#### The PREDIMED Study. Incidence of Invasive Breast Cancer According to Intervention Group

a solo





# Adherence to a Mediterranean Diet is associated with lower risk of overall incidence and cancer mortality

Current data points out to an inverse association between the adherence to the Mediterranean Diet and colorectal, breast, and prostate cancers.

More data are needed to define an inverse association between the adherence to the Mediterranean Diet and gastric, liver, and respiratory cancers.




# Mediterranean Diet, Cardiovascular Disease and Cancer

# Evidence on the benefits of the Mediterranean Diet on Secondary End Points (Mechanisms)

# **Oxidation and Inflammation**






Adjusted by sex, age, centre, and physical activity. Adjusted by LDL/HDL cholesterol ratio for lipid variables

Fitó M et al. Eur J Heart Fail, 2014



# The PREDIMED Study. MedDiet improves systemic oxidative damage in female with Metabolic Syndrome (n= 110). Mean ± SD




Adjusted by baseline and prevalence of the blood pressure MetS component

\* P<0.001 vs its baseline



Mitjavila MT et al. Clin Nutr 2012

#### Changes from baseline in plasma inflammatory biomarkers. The PREDIMED Study



Estruch et al. Ann Int Med, 2006. Olive oil and Nuts, traditional Mediterranean diet enriched with virgin olive oil or nuts, respectively



## Metanalysis of randomized controlled trials assessing the effects of an MedDiet on outcomes of endothelial function and inflammation.

17 trials (N= 2300) MetDiet adherence resulted in a

decrease [WMD, 95% CI] of :

- 1) hs CRP [ -0.98 mg/l, -1.48 to -0.49, p < 0.0001 ]
- 2) Interleukin-6 [ -0.42 pg/ml,-0.73 to -0.11, p = 0.008 ]

3) ICAM-1 [ -23.73 ng/ml, -41.24 to -6.22 p = 0.008 ]



Schwingshackl L and Hoffmann G . Nutr Metab Cardiovasc Dis, 2014

Molecular mechanisms by which the Mediterranean Diet can exert benefits for health

Nutrigenomics


Mediterranean diet modulate the expression of atherosclerosis-related genes toward a protective mode






Changes in inflammatory genes after 3-month consumption of Habitual diet (Control) and Mediterranean diet with washed virgin olive oil (TMD+WOO) or virgin olive oil (PC=366 mg/kg) (TMD+VOO) (n =90, healthy volunteers)


自己になす





Konstantinidou V et al. Mol. Nutr Food Res, 2013

#### The PREDIMED Study. PREDIGENE substudy (n=30, Microarray)



Ratio number of genes up-dowregulated/ Total genes that make up that pathway



# Conclusions

The Mediterranean Diet is an useful tool for protecting against cardiovascular disease and cancer

This protection involves a reduction of the lipid and DNA oxidative damage and of the chronic and acute inflammation

Molecular mechanims involved in vivo in humans

A nutrigenomic effect regulating the expression of atheroesclerosis-related genes toward a protective mode



## Primary Prevention by the Mediterranean Diet The PREDIMED Study



I.C.S.-División Primaria **IDIBAPS-Hospital Clínic** IMIM Univ.de Barcelona

We thank the participants in the trial for their enthusiastic and sustained collaboration and **Joan Vila from Institut Municipal** d'Investigació Mèdica, Barcelona, for expert assessment in the statistical analyses.

Indon





### ACKNOWLEDGEMENTS



Centro de Investigaciones Biomédicas en Red Physiopathology of Obesity and Nutrition. CIBERobn CB06/03 is an initiative of the Instituto de Salud Carlos III.



Unión Europea Fondo Europeo de Desarrollo Regional Una manera de hacer Europa

> GOBIERNO MINISTERIO DE ESPAÑA DE CIENCIA E INNOVACIÓN

Ministry of Science and Innovation "Spanish Network G03/140 AGL2005-05597; AGL2006-14228-C03-02/01 AGL2007-66638-C02-01; RETICS RD06/0045/0003 Programa INGENIO CONSOLIDER 2010, FUN-C-FOOD (CSD2007-063)



Ministerio de Sanidad y Consumo

Instituto de Salud Carlos III

Generalitat de Catalunya www.gencat.cat











- **NUPROAS Handelsbolag**
- (NUPROAS HB. www.nuproas.se)

# GRACIES PER LA VOSTRA ATENCIÓ









1. ¿Usa usted el aceite de oliva como principal grasa para cocinar?	Si = 1 punto	
2. ¿Cuanto aceite de oliva consume en total al día (incluyendo el usado para freir, comidas fuera de casa, ensaladas, etc.)?	4 o más cucharadas = 1 punto	
<ol> <li>¿Cuantas raciones de verdura u hortalizas consume al día? (las guarniciones o acompañamientos = 1/2 ración) 1 ración = 200g.</li> </ol>	2 o más (al menos una de ellas en ensalada o crudas) = 1 punto	
4. ¿Cuantas piezas de fruta (incluyendo zumo natural) consume al día?	3 o más al dia = 1 punto	
5. ¿Cuantas raciones de carnes rojas, hamburguesas, salchichas o embutidos consume al día? (ración: 100 - 150 g)	menos de 1 al dia = 1 punto	
6. ¿Cuantas raciones de mantequilla, margarina o nata consume al día? (porción individual: 12 g)	menos de 1 al dia = 1 punto	
7. ¿Cuantas bebidas carbonatadas y/o azucaradas (refrescos, colas, tónicas, bitter) consume al día?	menos de 1 al dia = 1 punto	

















# Encuesta de 14 puntos

8. ¿Bebe usted vino? ¿Cuánto consume a la semana?	7 o más vasos a la semana = 1 punto
9. ¿Cuantas raciones de legumbres consume a la semana? (1 plato o ración de 150 g)	3 o más a la semana = 1 punto
<ol> <li>¿Cuantas raciones de pescado-mariscos consume a la semana?</li> <li>(1 plato pieza o ración: 100 - 150 de pescado o 4-5 piezas o 200 g de marisco)</li> </ol>	3 o más a la semana = 1 punto
11. ¿Cuantas veces consume reposteria comercial (no casera) como galletas, flanes, dulce o pasteles a la semana?	menos de 2 a la semana = 1 punto
12. ¿Cuantas veces consume frutos secos a la semana? (ración 30 g)	3 o más a la semana = 1 punto
13. ¿Consume usted preferentemente carne de pollo, pavo o conejo e vez de ternera, cerdo, hamburguesas o salchichas? (carne de pollo: 1 pieza ración de 100 - 150 g)	
14. ¿Cuantas veces a la semana consume los vegetales cocinados, la pasta, arroz u otros platos aderezados con salsa de tomate, ajo, cebol o puerro elaborada a fuego lento con aceite de oliva (sofrito)?	



8. ¿Bebe usted vino? ¿Cuánto consume a la semana?	7 o más vasos a la semana 😑 1 punto	
9. ¿Cuantas raciones de legumbres consume a la semana? (1 plato o ración de 150 g)	3 o más a la semana 😑 1 punto	
<ol> <li>iCuantas raciones de pescado-mariscos consume a la semana?</li> <li>plato pieza o ración: 100 - 150 de pescado o 4-5 piezas o 200 g de marisco)</li> </ol>	3 o más a la semana 😑 1 punto	
11. ¿Cuantas veces consume reposteria comercial (no casera) como galletas, flanes, dulce o pasteles a la semana?	menos de 2 a la semana = 1 punto	
12. ¿Cuantas veces consume frutos secos a la semana? (ración 30 g)	3 o más a la semana 😑 1 punto	
14. ¿Cuantas veces a la semana consume los vegetales cocinados, la pasta, arroz u otros platos aderezados con salsa de tomate, ajo, cebollo o puerro elaborada a fuego lento con aceite de oliva (sofrito)?	a 2 o más a la semana = 1 punto	
	<ul> <li>9. ¿Cuantas raciones de legumbres consume a la semana? (1 plato o ración de 150 g)</li> <li>10. ¿Cuantas raciones de pescado-mariscos consume a la semana? (1 plato pieza o ración: 100 - 150 de pescado o 4-5 piezas o 200 g de marisco)</li> <li>11. ¿Cuantas veces consume reposteria comercial (no casera) como galletas, flanes, dulce o pasteles a la semana?</li> <li>12. ¿Cuantas veces consume frutos secos a la semana? (ración 30 g)</li> <li>13. ¿Consume usted preferentemente carne de pollo, pavo o conejo en vez de ternera, cerdo, hamburguesas o salchichas? (carne de pollo: 1 pieza o ración de 100 - 150 g)</li> <li>14. ¿Cuantas veces a la semana consume los vegetales cocinados, la pasta, arroz u otros platos aderezados con salsa de tomate, ajo, ceboll</li> </ul>	9. ¿Cuantas raciones de legumbres consume a la semana?       3 o más a la semana = 1 punto         10. ¿Cuantas raciones de pescado-mariscos consume a la semana?       3 o más a la semana = 1 punto         11. ¿Cuantas veces consume reposteria comercial (no casera) como galletas, flanes, dulce o pasteles a la semana?       menos de 2 a la semana = 1 punto         12. ¿Cuantas veces consume frutos secos a la semana? (ración 30 g)       3 o más a la semana = 1 punto         13. ¿Consume usted preferentemente carne de pollo, pavo o conejo en vez de ternera, cerdo, hamburguesas o salchichas? (carme de pollo: 1 pieza o ración de 100 - 150 g)       Sí = 1 punto         14. ¿Cuantas veces a la semana consume los vegetales cocinados, la pasta, arroz u otros platos aderezados con salsa de tomate, ajo, cebolla       2 o más a la semana = 1 punto





#### Measurements









\* Specific measurements Intervention compliance assessment Urinary tyrosol and hydroxytyrosol Plasma fatty acid composition (oleic and  $\alpha$ -linolenic acids)

Eligilibilty questionnaire	Х				
General questionnaire	Х				
Follow-up questionnaire		Х	Х	Х	Х
Food Freq. questionnaire	Х	Х	Х	Х	Х
14 item score of Med diet	Х	Х	Х	Х	Х
Physical activity ques.	Х	Х	Х	Х	Х
EKG, BP, and Anthropometric	Х	Х	Х	Х	Х
Blood samples *	Х	Х	Х	Х	Х
Fresh urine sample *	Х	Х	Х	Х	Х
Toenail sample	Х				



#### The PREDIMED Study. Subgroup analyses

P Value fo Interaction	tio (95% CI)	Hazard Ratio	Control Diet	Combined Mediterranean Diets	Subgroup
				no. of participants with event/total no. of	- •
0.62					Sex
.94)	0.69 (0.51-0.94)		64/987	107/2178	Male
.07)	0.73 (0.50-1.07)		45/1463	72/2819	Female
0.84					Age
.05)	0.73 (0.52-1.05)		47/1504	86/3272	<70 yr
.98)	0.71 (0.51-0.98)	<b></b>	62/946	93/1725	≥70 yr
0.63					Diabetes
.01)	0.67 (0.45-1.01)		40/1261	58/2572	No
.96)	0.71 (0.53-0.96)		69/1189	121/2425	Yes
0.06					Hypertension
45)	1.25 (0.64-2.45)		11/400	40/885	No
.84)	0.65 (0.50-0.84)		98/2050	139/4112	Yes
0.06					Dyslipidemia
.42)	0.95 (0.64-1.42)		36/687	77/1377	No
80)	0.60 (0.44-0.80)		73/1763	102/3620	Yes
0.75		i			Smoking
.94)	0.67 (0.47-0.94)		54/1527	80/3037	Never
.03)	0.75 (0.54-1.03)		55/923	99/1960	Ever
0.97					Family history of premature CHD
.94)	0.72 (0.55-0.94)		87/1890	144/3889	No
29)	0.75 (0.43-1.29)		22/560	35/1108	Yes
	· · · · · ·	0.5 1.0			



#### The PREDIMED Study. Subgroup analyses

Subgroup	Combined Mediterranean Diets no. of participants with event/total no. of	h primary end-point	Hazard Ratio	(95% CI)	P Value f Interacti
BMI			   		0.05
<25	18/399	7/164		0.69 (0.29-1.67)	
25-30	88/2316	37/1085		1.04 (0.71-1.54)	
>30	73/2282	65/1201		0.51 (0.37-0.71)	
Waist					0.72
<median< td=""><td>87/2561</td><td>48/1177</td><td></td><td>0.76 (0.53-1.08)</td><td></td></median<>	87/2561	48/1177		0.76 (0.53-1.08)	
≥Median	92/2436	61/1273		0.67 (0.48-0.93)	
Waist-to-height ratio	-	-			0.82
<median< td=""><td>81/2549</td><td>47/1182</td><td><b>_</b></td><td>0.74 (0.52-1.06)</td><td></td></median<>	81/2549	47/1182	<b>_</b>	0.74 (0.52-1.06)	
≥Median	98/2448	62/1268		0.68 (0.50-0.94)	
Baseline score for adherence to Medit	terranean diet				0.44
<9 (low)	93/2178	61/1256		0.81 (0.58-1.12)	
≥9 (high)	86/2819	48/1194		0.64 (0.45-0.92)	
End-point components					
Stroke	81/4997	58/2450		0.61 (0.44-0.86)	
Myocardial infarction	68/4997	38/2450		0.77 (0.52-1.15)	
Death from cardiovascular causes	57/4997	30/2450	<b>_</b>	0.83 (0.54-1.29)	
			0.5 1.0	2.0	
		Mediter	ranean Diets Better Control D	)iot Retter	





- 5

#### 2. RISK RATIO/ODDS RATIO ASSOCIATED WITH THE HIGHEST ADHERENCE TO MEDITERRANEAN DIETARY PATTERN.

•	Outcome	No of studies	Study type	Risk ratio/odds ratio	95% CI	I <sup>2</sup> (%)
•	Colorectal cancer	7	Combined	0.83	0.76-0.89	56
		3	Cohort	0.84	0.75-0.94	56
		4	Case-control	0.79	0.67-0.93	65
•	Breast cancer	12	Combined	0.93	0 <b>.87–0.99</b>	15
		4	Cohort	0.99	0.89-1.12	33
		8	Case-control	0.90	0.85-0.95	0
•	Prostate cancer	4	Combined	0.96	0.92-1.00	0
		3	Cohort	0.96	0.92-1.00	0
		1	Case-control	1.03	0.81-1.31	n.a
•	Gastric cancer	3	Combined	0.73	0.55-0.97	66
		2	Cohort	0.82	0.61-1.10	49
		1	Case-control	0.57	0.45-0.72	n.a
•	Liver cancer	2	Combined	0.58	0.46-0.73	
		1	Cohort	0.62	0.47-0.82	n.a
		1	Case-control	0.51	0.34-0.77	n.a
•	Esophageal cancer	2	Combined	0.49	0.22-1.09	83
		1	Cohort	0.68	0.34-1.36	n.a
		1	Case-control	0.26	0.13-0.52	n.a
•	Head and neck cancer	4	Combined	0.40	0.24-0.66	90
		1	Cohort	0.61	0.33-1.14	n.a
		3	Case-control	0.32	0.19-0.55	83
•	Endometrial cancer	3	Combined	0.72	0.40-1.31	94
		1	Cohort	0.98	0.82 - 1.17	n.a
		2	Case-control	0.61	0.29-1.29	89
•	Respiratory cancer	1	Cohort	0.10	0.10-0.70	n.a
•	Bladder cancer	1	Cohort	0.84	0.69-1.02	n.a
•	Pancreatic cancer	1	Case-control	0.48	0.35-0.66	n.a

. With respect to types of cancer, the positive effects of an MD on colorectal carcinoma demonstrated in the first analysis could be confirmed by the inclusion of new studies. Additional evidence could be found with respect to distinct types of cancer such as liver cancer, or head and neck cancer, which were either not depicted in the original analysis due to lack of corresponding studies or had to be rearranged to fit into the adapted classification of cancer types used for the update. Furthermore, an inverse association could be observed for breast cancer and gastric cancer risk (taking into account the exclusion of Tognon et al., who reported only on cancer-specific mortality cases). Some data must be interpreted with caution, since the number of observations dealing with these types of cancer are

still low (e.g., liver cancer). Likewise, the effects of an MD on breast cancer will remain a matter of debate. The inverse association of an MD dietary pattern after pooling only case-control studies was present in the original analysis and is now further substantiated by three additional studies. However, pooling cohort studies (which are characterized by a higher level of evidence) did not confirm these results (there are no additional cohorts in this update). For future studies, it might be interesting to differentiate between post and premenopausal breast cancer or even to classify breast cancer according to receptor type.

. However, we could not find a significant correlation

between adherence to an MD and risk of cancer mortality

and cancer recurrence.







The protocol for the control group was changed halfway through the trial (October 2006). A lower intensity of dietary intervention for the control group during the first few years might have caused a bias toward a benefit in the Mediet groups, since the participants in these groups received a more intensive intervention during that time.

However, we found no significant interaction between the period of trial enrollment (before vs. after the protocol change) and the benefit in the Mediet groups.



# Other specific aims

- To determine the changes in blood lipids, blood pressure, markers of oxidation and inflammation and other intermediate markers of cardiovascular risk to better understand how dietary changes are able to modify the risk of clinical events
- To identify the subjects with certain phenotypic and genotypic characteristics that benefit more from a Mediterranean diet



 To assess the effect of the MedDiet on the nutrigenomic response of atherosclerosis-related genes



# **The PREDIMED Study-Limitations**

The generalizability of our findings is limited because all the study participants lived in a Mediterranean country and were at high cardiovascular risk.

Whether the results can be generalized to persons at lower

risk or to other settings requires further research.



#### **PRIMARY END-POINT**

### Composite of:

- Cardiovascular death
- Non-fatal myocardial infarction
- Non-fatal stroke

## SECONDARY END-POINTS

- Cardiovascular death
- Non-fatal myocardial infarction
- Non-fatal stroke
- Death from any cause
- Angina leading to revascularization procedure
- Heart failure



Evidence pro the Mediterranean type Diet. Clinical Trials. Secondary End Points

### Effect of a Mediterranean-Style Diet, on Endothelial Dysfunction, Vascular Inflammation in the metabolic Syndrome.

Esposito K , Marfella R, Ciotola M, et al. JAMA 2004;292:1440-1446

# **180 Italians with Metabolic Syndrome. 2 years-Intervention study.**

Significative reductions in :

- hs-CRP , Interleukines ,
- BMI,
- Glucose. Insulin, HOMA
- SBP and DBP
- Total cholesterol and triglycerides



**Increase in HDL cholesterol** 

# Forest plot of the association between a 2-point increase of adherence score to the Mediterranean diet and the risk of all-cause mortality.

	Study		Rela	tive risk (	95% C	[)		Weight (%)	Relative risk (95% CI)
	<b>Trichopoulou</b> (1995) (18)							0.3	<b>0.69</b> (0.48, 0.99)
	<b>Kouris-Blazos</b> (1999) (19)					_		0.2	<b>0.79</b> (0.50, 1.25)
	Lasheras (2000) (20)	<b>←</b> ∎			+			0.1	<b>0.48</b> (0.22, 1.03)
K	<b>Knoops</b> (2004) (7)			-8-				7.9	<b>0.88</b> (0.82, 0.94)
	<b>Trichopoulou</b> (2005) (21)							14.7	<b>0.93</b> (0.89, 0.97)
	Lagiou (2006) (8)			-	+			3.2	<b>0.93</b> (0.83, 1.04)
	<b>Mitrou</b> (2007) (M) (9)							37	<b>0.92</b> (0.91, 0.94)
	<b>Mitrou</b> (2007) (F) (9)			÷				30.7	<b>0.93</b> (0.91, 0.95)
V.	<b>Trichopoulou</b> (2009) (14)			-				6.1	<b>0.86</b> (0.80, 0.93)
	Total (95% CI)							100	<b>0.92</b> (0.90, 0.94)
2-		0.4	0.6	0.8	1	1.2	1.4	100	0.72 (0.70, 0.74)
h		Red	uced risl		In	creased	risk		

10 by American Society for Nutrition

Sofi F et al. Am J Clin Nutr 2010;92:1189-1196

# **PREDIMED Participants**

いい

	Mediet + VOO	MeDiet + Nuts	Control
	(n= 2543)	(n=2454)	(n=2450)
Age (SD)	67 (6)	67 (6)	67 (6)
Women (%)	57	54	58
Diabetes (%)	50	47	48
Hypertension (%)	82	82	84
Current smokers (%)	14	15	14
Dyslipidemia (%)	72	73	72
BMI, kg/m² (SD)	30 (4)	30 (4)	30 (4)
Waist circumf. (SD)	100 (10)	100 (10)	101 (11)
Med Diet 0-14 pts. (SD)	8.7 (2)	8.7 (2)	8.3 (2)